Nebivolol
Indications
Registered South African indications:
- Hypertension
Cautions
Contraindications
- Hypersensitivity to the active ingredient or any of its excipients
- Liver insufficiency or liver function impairment
- Acute heart failure, cardiogenic shock or episodes of heart failure decompensation requiring IV inotropic therapy
- Pregnancy
- Breastfeeding
- Cardiogenic shock
- Uncontrolled heart failure
- Sick sinus syndrome, including sino-atrial block
- Second- and third-degree heart block (without a pacemaker)
- History of bronchospasm and bronchial asthma
- Untreated phaeochromocytoma
- Metabolic acidosis
- Bradycardia (heart rate <60bpm prior to start of therapy)
- Hypotension (systolic blood pressure <90mm Hg)
- Severe peripheral circulatory disturbances
- In combination with verapamil therapy
Cautions
- Severe renal impairment
- Elderly
- Unstable congestive cardiac failure
- Ischaemic heart disease
- First degree heart block
- Vasospastic (Prinzmetal's) angina
- Diabetes mellitus
- Hyperthyroidism
- Chronic obstructive pulmonary disease
- Psoriasis
- History of allergic reactions
- Abruption cessation
- Galactose intolerance
- Lapp lactase deficiency
- Glucose-galactose malabsorption
Adult dosage
Forms avail. in SA and covered in this monograph: tab
Hypertension - mild, moderate
- Oral (tab): 5mg, dly
Cardiac failure
- Oral (tab): 1.25mg, dly; Titrate by doubling dose at 1-2 week intervals; Maintenance: 10mg, dly; Max dose: 10mg/24hrs
Paediatric dosage
Not established for use in children below 18 years
Special populations
Pregnancy
- Contraindicated
Breastfeeding
- Contraindicated
Renal Impairment
- Severe: Caution; no information available
Hepatic Impairment
- Contraindicated
Contraindicated for liver insufficiency or liver function impairment
Elderly
- Caution; dose adjustment recommended
Adverse reactions
Central Nervous System Disorders
- Nightmares
- Depression
- Headache
- Dizziness
- Paraesthesia
- Syncope
Cardiovascular Disorders
- Bradycardia
- Heart failure
- Slowed atrioventricular conduction
- Atrioventricular block
- Hypotension
- Intermittent claudication
Respiratory Disorders
- Dyspnoea
- Bronchospasm
Gastrointestinal Disorders
- Constipation
- Nausea and vomiting
- Diarrhoea
- Dyspepsia
- Flatulence
Genitourinary Disorders
- Impotence
Skin and Subcutaneous Tissue Disorders
- Pruritus
- Rash
- Psoriasis
- Urticaria
Immune, Blood and Lymphatic System Disorders
- Angioneurotic oedema
- Hypersensitivity
Interactions
- Class I antiarrythmics
- Calcium channel blockers
- Verapamil
- Centrally-acting antihypertensives
- Amioderone
- Halogenated anaesthetics
- Insulin
- Antidiabetic agents
- Baclofen
- Amifostine
- Digoxin
- Antipsychotics
- Antidepressants
- Non-steroidal anti-inflammatory drugs
- Sympathomimetics
- Cimetidine
- Nicardipine
Monitoring
None routine. Specific cases may require
- Blood glucose
- ECG
Mechanism of action
Nebivolol is a competitive and selective beta-receptor antagonist which has mild vasodilating properties.
Dosage forms
- Tablet
Formulation
Tablet 5mg
- Lovispes (Akacia) originator
- Nebilet (Adcock) originator
References
1. https://www.medicines.org.uk/emc/medicine/9145 10 February 2015 A. Menarini Farmaceutica Internazionale SRL 5mg tablet 2. https://www.medicines.org.uk/emc/medicine/26209 22 April 2015 Zentiva 3. SAMF_Page 155 4. http://home.intekom.com/pharm/adcock/nebilet.html 5. https://drive.google.com/drive/folders/10Gsqh9X1Io7z8MYdQLU-OUCaQC48i_SY (1/11/2000_Adcock_Nebilet_5mg_tab) 6. https://drive.google.com/drive/folders/10Gsqh9X1Io7z8MYdQLU-OUCaQC48i_SY (02/02/2015_Akacia_Lovispes_tab) 7. PI - NEBILET 5 mg tablets, LeBasi Pharmaceuticals (Pty) Ltd - DATE OF REVISION OF THE TEXT 18 April 2024 Downloaded from SAHPRA 16 Oct 2024 [https://pi-pil-repository.sahpra.org.za/wp-content/uploads/2024/05/PI_Nebilet-340495_18.04.2024.pdf]
Brands & products
2 products · stale NAPPI snapshot · refreshed 5/28/2026 · 159 days oldtabletGeneric· 2 products
from R8.44/unit| Product | Strength | Pack | Sched | SEP | Unit | Disp fee | NAPPI |
|---|---|---|---|---|---|---|---|
| Nebilet | 5 mg | 30 | S3 | R253.21 | R8.44 | R94.87 | 700558003 |
| Lovispes | 5 mg | 30 | S3 | R372.67 | R12.42 | R127.73 | 716483001 |
- Lovispes
- Nebilet
Medical aid coverage
data not yet integrated- Comprehensive Series—
- Executive Plan—
- KeyCare Series—
- Priority Series—
- Saver Series—
Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.
- BonClassic—
- BonComprehensive—
- BonEssential—
- BonFit Select—
- BonSave—
- BonStart—
Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.
- Beryl—
- Emerald—
- Onyx—
- Ruby—
- Sapphire—
- Tanzanite One—
Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.
- Aquarium Option—
- Efficiency Option—
- Marine Option—
Formulary scraper pending — coverage tier, co-pay and authorisation requirements will appear here once data is ingested.